These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 9404418

  • 1. [A case of apparent mineralocorticoid excess caused by type 2 11 beta- hydroxysteroid dehydrogenase deficiency].
    Morineau G, Pascoe L, Marc JM, Caillette A, Krozowski Z, Corvol P, Fiet J.
    Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1111-5. PubMed ID: 9404418
    [Abstract] [Full Text] [Related]

  • 2. Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess.
    Whorwood CB, Stewart PM.
    J Hypertens Suppl; 1996 Dec; 14(5):S19-24. PubMed ID: 9120678
    [Abstract] [Full Text] [Related]

  • 3. Apparent mineralocorticoid excess.
    Funder JW.
    Endocrinol Metab Clin North Am; 1995 Sep; 24(3):613-21. PubMed ID: 8575412
    [Abstract] [Full Text] [Related]

  • 4. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase.
    Mune T, Rogerson FM, Nikkilä H, Agarwal AK, White PC.
    Nat Genet; 1995 Aug; 10(4):394-9. PubMed ID: 7670488
    [Abstract] [Full Text] [Related]

  • 5. [Syndrome of apparent mineralocorticoid excess caused by a deficiency of 11 beta-hydroxysteroid dehydrogenase: clinical and genetic study in a Chilean family followed for 19 years].
    Rodríguez JA.
    Rev Med Chil; 2000 Jan; 128(1):17-26. PubMed ID: 10883518
    [Abstract] [Full Text] [Related]

  • 6. Apparent mineralocorticoid excess.
    Benediktsson R, Edwards CR.
    J Hum Hypertens; 1994 May; 8(5):371-5. PubMed ID: 8064785
    [Abstract] [Full Text] [Related]

  • 7. [Mineralocorticoid-like hypertension. "Apparent mineralocorticoid excess". A hereditary type of hypertension?].
    Christensen TH, Kaae HH, Ibsen H.
    Ugeskr Laeger; 1999 Oct 18; 161(42):5800-3. PubMed ID: 10578695
    [Abstract] [Full Text] [Related]

  • 8. A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
    Odermatt A, Dick B, Arnold P, Zaehner T, Plueschke V, Deregibus MN, Repetto H, Frey BM, Frey FJ, Ferrari P.
    J Clin Endocrinol Metab; 2001 Mar 18; 86(3):1247-52. PubMed ID: 11238516
    [Abstract] [Full Text] [Related]

  • 9. Apparent mineralocorticoid excess syndrome: report of one family with three affected children.
    Al-Harbi T, Al-Shaikh A.
    J Pediatr Endocrinol Metab; 2012 Mar 18; 25(11-12):1083-8. PubMed ID: 23329753
    [Abstract] [Full Text] [Related]

  • 10. [11 beta-hydroxysteroid dehydrogenase type 2 activity in Chilean patients with hypertension].
    Mosso L, Carvajal C, Campino C, Rojas A, González A, Barraza A, Montero J, Fardella C.
    Rev Med Chil; 2002 Nov 18; 130(11):1201-8. PubMed ID: 12587501
    [Abstract] [Full Text] [Related]

  • 11. 11 beta-Hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
    White PC, Mune T, Rogerson FM, Kayes KM, Agarwal AK.
    Pediatr Res; 1997 Jan 18; 41(1):25-9. PubMed ID: 8979285
    [Abstract] [Full Text] [Related]

  • 12. Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency.
    Nikkilä H, Tannin GM, New MI, Taylor NF, Kalaitzoglou G, Monder C, White PC.
    J Clin Endocrinol Metab; 1993 Sep 18; 77(3):687-91. PubMed ID: 8370690
    [Abstract] [Full Text] [Related]

  • 13. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.
    Stewart PM, Corrie JE, Shackleton CH, Edwards CR.
    J Clin Invest; 1988 Jul 18; 82(1):340-9. PubMed ID: 3164727
    [Abstract] [Full Text] [Related]

  • 14. Furosemide and 11beta-hydroxysteroid dehydrogenase activity, in man.
    Palermo M, Armanini D, Shackleton CH, Sorba G, Cossu M, Roitman E, Scaroni C, Delitala G.
    Exp Clin Endocrinol Diabetes; 2002 Sep 18; 110(6):272-6. PubMed ID: 12373630
    [Abstract] [Full Text] [Related]

  • 15. Apparent mineralocorticoid excess: report of six new cases and extensive personal experience.
    Morineau G, Sulmont V, Salomon R, Fiquet-Kempf B, Jeunemaître X, Nicod J, Ferrari P.
    J Am Soc Nephrol; 2006 Nov 18; 17(11):3176-84. PubMed ID: 17035606
    [Abstract] [Full Text] [Related]

  • 16. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess.
    White PC, Mune T, Agarwal AK.
    Endocr Rev; 1997 Feb 18; 18(1):135-56. PubMed ID: 9034789
    [Abstract] [Full Text] [Related]

  • 17. Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure.
    Homma M, Tanaka A, Hino K, Takamura H, Hirano T, Oka K, Kanazawa M, Miwa T, Notoya Y, Niitsuma T, Hayashi T.
    Metabolism; 2001 Jul 18; 50(7):801-4. PubMed ID: 11436185
    [Abstract] [Full Text] [Related]

  • 18. 11beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
    White PC.
    Am J Med Sci; 2001 Dec 18; 322(6):308-15. PubMed ID: 11780688
    [Abstract] [Full Text] [Related]

  • 19. Administration of glycyrrhetinic acid: significant correlation between serum levels and the cortisol/cortisone-ratio in serum and urine.
    Heilmann P, Heide J, Hundertmark S, Schöneshöfer M.
    Exp Clin Endocrinol Diabetes; 1999 Dec 18; 107(6):370-8. PubMed ID: 10543414
    [Abstract] [Full Text] [Related]

  • 20. Apparent mineralocorticoid excess syndromes.
    Shimojo M, Stewart PM.
    J Endocrinol Invest; 1995 Dec 18; 18(7):518-32. PubMed ID: 9221270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.